Search Results

American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies powering its clinical pipeline, announced today that Agustin Legido, MD, PhD, MBA has joined its Scientific and Medical Advisory Board.

American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies that powers its clinical pipeline, announced today that it has received U.S. Food and Drug Administration (FDA) approval to proceed with a Phase I Clinical Trial for the treatment of Long COVID/PASC.

American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (“Aires” or the “Company”), a pioneer in innovative technology designed to safeguard against electromagnetic radiation and enhance human well-being, issues this news release in order to clarify certain financial disclosure contained in its news release dated June 18, 2024 (the “June 18th Press Release”).

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American College of Cardiology (ACC.24) at the Georgia World Congress Center in Atlanta, GA, April 6 – 8, 2024.

American CryoStem Corporation, a leading clinical-stage biotechnology developer of adipose-derived stem cell therapies announced completion of its Phase I clinical protocol design for the treatment of Long COVID.

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting from June 20-22nd, 2024 at the Rosen Shingle Creek Resort in Orlando, Florida.

American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (“Aires” or the “Company”), a pioneer in innovative technology designed to safeguard against electromagnetic radiation and enhance human well-being, is pleased to share a corporate update highlighting the Company’s strong growth and promising future outlook. Despite recent stock price fluctuations, Aires’ fundamentals remain solid, and the Company continues to execute its strategic plan with precision and vigor.

American CryoStem Corporation, a leading clinical-stage biotechnology developer of adipose tissue-based cellular technologies for Regenerative and Personalized Medicine announced that it has added John “Jay” Schwartz, PhD to its Scientific and Medical Advisory Board.

American CryoStem Corporation, a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced that it has completed the development of a new standardized wound healing protocol utilizing its tissue based technologies with Advanced Regenerative Associates.

American CryoStem Corporation a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and cellular therapies, announced that it has reached the midway point of its ATCell™ autologous mesenchymal stem cell therapy for Phase I Clinical Trial for Post-concussion syndrome.